Procter & Gamble Health Intrinsic Value
Procter & Gamble Health intrinsic value. Procter & Gamble Health (PGHL) median intrinsic value is ₹3029.41 from 10 valuation models (range ₹1060–₹8200), vs current price ₹5300.00 — -42.8% downside (Trading Above Calculated Value), margin of safety -75.0%. For current market price and key ratios, visit Procter & Gamble Health stock price NSE.
PGHL Valuation Methods Summary — DCF, Graham Number & P/E
Procter & Gamble Health intrinsic value across 10 models vs current price ₹5300.00 — upside/downside and value range per method. Read PGHL dividend track record for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹4730.00 | ₹3784.00 - ₹5676.00 | -10.8% | EPS: ₹215.00, Sector P/E: 22x |
| Book Value Method | asset | ₹1060.00 | ₹954.00 - ₹1166.00 | -80.0% | Book Value/Share: ₹308.82, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1743.53 | ₹1569.18 - ₹1917.88 | -67.1% | Revenue/Share: ₹871.76, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3029.41 | ₹2726.47 - ₹3332.35 | -42.8% | EBITDA: ₹515.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2700.69 | ₹2160.55 - ₹3240.83 | -49.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2016.23 | ₹1814.61 - ₹2217.85 | -62.0% | EPS Growth: 11.7%, Fair P/E: 9.4x |
| Growth Adjusted P/E | growth | ₹3295.79 | ₹2966.21 - ₹3625.37 | -37.8% | Revenue Growth: 4.4%, Adj P/E: 15.3x |
| ROE Based Valuation | profitability | ₹3360.00 | ₹3024.00 - ₹3696.00 | -36.6% | ROE: 68.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1590.00 | ₹1431.00 - ₹1749.00 | -70.0% | EPS: ₹215.00, BVPS: ₹308.82 |
| Dividend Yield Method | dividend | ₹8200.00 | ₹7380.00 - ₹9020.00 | +54.7% | DPS: ₹205.00, Target Yield: 2.5% |
PGHL Intrinsic Value vs Market Price — All Valuation Models
Procter & Gamble Health fair value range ₹1060–₹8200 vs current market price ₹5300.00 across 10 valuation models. Compare with Procter & Gamble Health valuation methods to assess whether the stock is under or overvalued.
PGHL Intrinsic Value Analysis — Undervalued or Overvalued?
Procter & Gamble Health median intrinsic value ₹3029.41, current price ₹5300.00 — Trading Above Calculated Value by 42.8%, margin of safety -75.0%.
What is the intrinsic value of PGHL?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Procter & Gamble Health (PGHL) is ₹3029.41 (median value). With the current market price of ₹5300.00, this represents a -42.8% variance from our estimated fair value.
The valuation range spans from ₹1060.00 to ₹8200.00, indicating ₹1060.00 - ₹8200.00.
Is PGHL undervalued or overvalued?
Based on our multi-method analysis, Procter & Gamble Health (PGHL) appears to be trading above calculated value by approximately 42.8%.
PGHL Financial Health — Key Ratios vs Industry Benchmarks
Procter & Gamble Health financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.97 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 68.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 33.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.76x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
PGHL Cash Flow Quality — Operating & Free Cash Flow
Procter & Gamble Health operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹338 Cr | ₹338 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹169 Cr | ₹169 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹228 Cr | ₹225 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹236 Cr | ₹225 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹170 Cr | ₹157 Cr | Positive Free Cash Flow | 8/10 |